Lantheus Holdings, Inc. (LNTH)
USD 102.1
(3.64%)
USD 102.1
(3.64%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 344.9 Million USD | -36.77% |
| 2022 | 545.5 Million USD | 106.8% |
| 2021 | 263.78 Million USD | 84.52% |
| 2020 | 142.95 Million USD | 16.09% |
| 2019 | 123.15 Million USD | 11.55% |
| 2018 | 110.39 Million USD | 0.1% |
| 2017 | 110.28 Million USD | 25.93% |
| 2016 | 87.57 Million USD | -5.82% |
| 2015 | 92.99 Million USD | 8.0% |
| 2014 | 86.1 Million USD | -12.78% |
| 2013 | 98.72 Million USD | -10.71% |
| 2012 | 110.56 Million USD | -1.72% |
| 2011 | 112.49 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 153.14 Million USD | 1.15% |
| 2024 Q1 | 151.39 Million USD | 63.88% |
| 2023 Q2 | 78.5 Million USD | -9.16% |
| 2023 Q1 | 86.42 Million USD | -74.5% |
| 2023 FY | 344.9 Million USD | -36.77% |
| 2023 Q4 | 92.38 Million USD | 5.47% |
| 2023 Q3 | 87.59 Million USD | 11.57% |
| 2022 Q4 | 338.84 Million USD | 449.28% |
| 2022 Q1 | 70.14 Million USD | -24.77% |
| 2022 Q2 | 74.82 Million USD | 6.67% |
| 2022 Q3 | 61.69 Million USD | -17.55% |
| 2022 FY | 545.5 Million USD | 106.8% |
| 2021 FY | 263.78 Million USD | 84.52% |
| 2021 Q1 | 40.67 Million USD | 3.81% |
| 2021 Q3 | 56.99 Million USD | -21.78% |
| 2021 Q4 | 93.24 Million USD | 63.6% |
| 2021 Q2 | 72.86 Million USD | 79.17% |
| 2020 Q4 | 39.17 Million USD | -5.62% |
| 2020 Q3 | 41.51 Million USD | 32.23% |
| 2020 FY | 142.95 Million USD | 16.09% |
| 2020 Q2 | 31.39 Million USD | 1.67% |
| 2020 Q1 | 30.87 Million USD | -3.89% |
| 2019 Q4 | 32.12 Million USD | -2.86% |
| 2019 Q1 | 27.91 Million USD | 3.77% |
| 2019 Q2 | 30.03 Million USD | 7.6% |
| 2019 FY | 123.15 Million USD | 11.55% |
| 2019 Q3 | 33.07 Million USD | 10.11% |
| 2018 Q2 | 27.92 Million USD | 2.75% |
| 2018 FY | 110.39 Million USD | 0.1% |
| 2018 Q1 | 27.17 Million USD | -5.3% |
| 2018 Q4 | 26.9 Million USD | -5.28% |
| 2018 Q3 | 28.4 Million USD | 1.73% |
| 2017 FY | 110.28 Million USD | 25.93% |
| 2017 Q3 | 25.7 Million USD | -8.36% |
| 2017 Q2 | 28.05 Million USD | 0.77% |
| 2017 Q1 | 27.83 Million USD | 24.34% |
| 2017 Q4 | 28.69 Million USD | 11.62% |
| 2016 Q2 | 21.68 Million USD | -0.76% |
| 2016 FY | 87.57 Million USD | -5.82% |
| 2016 Q4 | 22.38 Million USD | 3.42% |
| 2016 Q1 | 21.85 Million USD | 4.11% |
| 2016 Q3 | 21.64 Million USD | -0.2% |
| 2015 Q2 | 27.31 Million USD | 11.97% |
| 2015 Q1 | 24.39 Million USD | 15.96% |
| 2015 Q3 | 20.29 Million USD | -25.68% |
| 2015 FY | 92.99 Million USD | 8.0% |
| 2015 Q4 | 20.99 Million USD | 3.43% |
| 2014 Q2 | 21.07 Million USD | -2.29% |
| 2014 FY | 86.1 Million USD | -12.78% |
| 2014 Q4 | 21.03 Million USD | -6.17% |
| 2014 Q3 | 22.41 Million USD | 6.35% |
| 2014 Q1 | 21.57 Million USD | 5.37% |
| 2013 FY | 98.72 Million USD | -10.71% |
| 2013 Q1 | 32.04 Million USD | 22.55% |
| 2013 Q2 | 24.7 Million USD | -22.93% |
| 2013 Q3 | 21.5 Million USD | -12.95% |
| 2013 Q4 | 20.47 Million USD | -4.78% |
| 2012 FY | 110.56 Million USD | -1.72% |
| 2012 Q4 | 26.15 Million USD | 0.0% |
| 2011 FY | 112.49 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bright Green Corporation | 8.25 Million USD | -4079.163% |
| Alpha Teknova, Inc. | 45.85 Million USD | -652.09% |
| ANI Pharmaceuticals, Inc. | 195.98 Million USD | -75.985% |
| Aquestive Therapeutics, Inc. | 44.85 Million USD | -668.941% |
| Collegium Pharmaceutical, Inc. | 159.2 Million USD | -116.635% |
| Cosmos Health Inc. | 26.18 Million USD | -1217.382% |
| Journey Medical Corporation | 54.59 Million USD | -531.756% |
| Embecta Corp. | 528.4 Million USD | 34.727% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -26.85% |
| Dynavax Technologies Corporation | 219.14 Million USD | -57.385% |
| Intra-Cellular Therapies, Inc. | 590 Million USD | 41.543% |
| Pacira BioSciences, Inc. | 326.37 Million USD | -5.676% |
| PainReform Ltd. | 9.58 Million USD | -3498.717% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -2527.923% |
| Sunshine Biopharma, Inc. | 13.12 Million USD | -2527.923% |
| SCYNEXIS, Inc. | 51.84 Million USD | -565.216% |
| Safety Shot Inc | 12.1 Million USD | -2748.14% |
| China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -11137.533% |
| Procaps Group, S.A. | 199.47 Million USD | -72.903% |
| Theratechnologies Inc. | 72.75 Million USD | -374.052% |
| Harrow Health, Inc. | 89.97 Million USD | -283.338% |
| Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -3551.292% |
| Biofrontera Inc. | 39.95 Million USD | -763.137% |
| DURECT Corporation | 43.71 Million USD | -688.976% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 34.803% |
| Cronos Group Inc. | 96.7 Million USD | -256.638% |
| OptiNose, Inc. | 85.1 Million USD | -305.28% |
| Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | -48.585% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -780.906% |
| RedHill Biopharma Ltd. | -9.56 Million USD | 3707.374% |
| Organogenesis Holdings Inc. | 314.13 Million USD | -9.794% |
| Guardion Health Sciences, Inc. | 9.73 Million USD | -3444.414% |
| Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -701.34% |
| Radius Health, Inc. | 265.92 Million USD | -29.697% |
| Universe Pharmaceuticals INC | 13.84 Million USD | -2391.716% |
| ProPhase Labs, Inc. | 37.85 Million USD | -811.183% |
| Phibro Animal Health Corporation | 260.29 Million USD | -32.502% |
| Procaps Group S.A. | 187.24 Million USD | -84.198% |
| Alvotech | 285.43 Million USD | -20.832% |
| TherapeuticsMD, Inc. | 9.82 Million USD | -3410.443% |
| Viatris Inc. | 5.96 Billion USD | 94.219% |
| Rockwell Medical, Inc. | 15.37 Million USD | -2143.404% |
| Aytu BioPharma, Inc. | 59.84 Million USD | -476.372% |
| SIGA Technologies, Inc. | 22.04 Million USD | -1464.672% |
| Tilray Brands, Inc. | 251.35 Million USD | -37.216% |
| Lifecore Biomedical, Inc. | 49.03 Million USD | -603.334% |
| Shineco, Inc. | 17.94 Million USD | -1821.664% |
| PetIQ, Inc. | 192.72 Million USD | -78.96% |
| Regencell Bioscience Holdings Limited | 3.99 Million USD | -8541.671% |
| Incannex Healthcare Limited | 30.05 Million USD | -1047.642% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | 78.396% |
| Alimera Sciences, Inc. | 62.64 Million USD | -450.599% |
| Silver Spike Investment Corp. | 762.49 Thousand USD | -45133.393% |
| Assertio Holdings, Inc. | 368.58 Million USD | 6.426% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -5760.111% |
| Petros Pharmaceuticals, Inc. | 17.8 Million USD | -1836.718% |
| Clever Leaves Holdings Inc. | 21.16 Million USD | -1529.274% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1539.1% |
| Avadel Pharmaceuticals plc | 164.96 Million USD | -109.074% |
| Hempacco Co., Inc. | 7.59 Million USD | -4440.292% |
| Talphera, Inc. | 11.99 Million USD | -2775.613% |
| Alvotech | 285.43 Million USD | -20.832% |
| Eagle Pharmaceuticals, Inc. | 140.71 Million USD | -145.108% |
| Currenc Group, Inc. | 24 Million USD | -1336.962% |
| Kamada Ltd. | 45.42 Million USD | -659.259% |
| Indivior PLC | 911 Million USD | 62.14% |
| Evoke Pharma, Inc. | 12.4 Million USD | -2679.299% |
| Flora Growth Corp. | 10.57 Million USD | -3160.242% |
| Cyclo Therapeutics, Inc. | 21.04 Million USD | -1539.1% |
| Evolus, Inc. | 189.75 Million USD | -81.757% |
| HUTCHMED (China) Limited | 436.23 Million USD | 20.936% |
| Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | -123.767% |
| Akanda Corp. | 3.48 Million USD | -9800.968% |